Single‐Dose Pharmacokinetics and Tolerability of the Oral Epidermal Growth Factor Receptor Inhibitor Mobocertinib (TAK‐788) in Healthy Volunteers: Low‐Fat Meal Effect and Relative Bioavailability of 2 Capsule Products-Reference-Cited by-同舟云学术

Single‐Dose Pharmacokinetics and Tolerability of the Oral Epidermal Growth Factor Receptor Inhibitor Mobocertinib (TAK‐788) in Healthy Volunteers: Low‐Fat Meal Effect and Relative Bioavailability of 2 Capsule Products

Published:2021-06-12 Issue:9 Volume:10 Page:1028-1043
ISSN:2160-763X
Container-title:Clinical Pharmacology in Drug Development
language:en
Short-container-title:Clinical Pharmacology in Drug Development

Author:

Zhang Steven¹,Jin Shu¹,Griffin Celina¹,Feng Zhongling¹,Lin Jianchang¹,Baratta Mike¹,Brake Rachael¹,Venkatakrishnan Karthik¹,Gupta Neeraj¹

Affiliation:

1. Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, USA a wholly owned subsidiary of Takeda Pharmaceutical Company Limited

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpdd.951

Reference33 articles.

1. Cancer of the lung and bronchus (invasive);Howlader N;SEER Cancer Statistics Review 1975‐2016,2019

2. Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: Focus on epidermal growth factor receptor mutation testing and mutation-positive patients

3. EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications

4. Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions

5. Epidermal growth factor receptor exon 20 mutation in lung cancer: types, incidence, clinical features and impact on treatment

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A phase 1 study to assess the absolute bioavailability, mass balance, pharmacokinetics, metabolism, and excretion of [14C]-mobocertinib, an oral inhibitor of EGFR exon 20 insertion mutations, in healthy participants;Investigational New Drugs;2024-05-24

2. Mobocertinib: Mechanism of action, clinical, and translational science;Clinical and Translational Science;2024-03

3. Isolation, identification and structural characterization of forced degradation products of mobocertinib using LC-MS/MS and NMR;Results in Chemistry;2024-01

4. A Perspective of the Amide Group Containing FDA Approved Anticancer Drugs from 2021–2022 (A Review);Russian Journal of Bioorganic Chemistry;2023-11

5. Therapeutic Drug Monitoring of Protein Kinase Inhibitors in the Treatment of Non-small Cell Lung Cancer;Prague Medical Report;2023